deuterium has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balasubramaniam, D; Boyles, J; Coleman, K; Foster, D; Griffin, PR; Hughes, K; O'Leary, TR | 1 |
| Auclair, K; Belovodskiy, A; Donnelly, BL; Lemieux, MJ; Nieman, JA; Piercey, A; Reiz, B; Van Oers, TJ; Vederas, JC; Vuong, W | 1 |
| Battaile, KP; Chang, KO; Dampalla, CS; Groutas, WC; Kashipathy, MM; Kim, Y; Lovell, S; Meyerholz, DK; Nguyen, HN; Perera, KD; Perlman, S; Wong, LR; Zheng, J | 1 |
3 other study(ies) available for deuterium and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Hydrogen-Deuterium Exchange Epitope Mapping of Glycosylated Epitopes Enabled by Online Immobilized Glycosidase.
Topics: Antibodies, Monoclonal; COVID-19; Deuterium; Deuterium Exchange Measurement; Epitope Mapping; Epitopes; Glycoside Hydrolases; Humans; Hydrogen; SARS-CoV-2 | 2023 |
Deuteration for Metabolic Stabilization of SARS-CoV-2 Inhibitors GC373 and Nirmatrelvir.
Topics: Antiviral Agents; COVID-19; Deuterium; Humans; Ritonavir; SARS-CoV-2 | 2023 |
Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.
Topics: Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Coronavirus 3C Proteases; Coronavirus Papain-Like Proteases; COVID-19; COVID-19 Drug Treatment; Crystallography, X-Ray; Deuterium; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Lung; Mice; Mice, Transgenic; Models, Molecular; Molecular Structure; Protease Inhibitors; Protein Conformation; Pyrrolidines; SARS-CoV-2; Sulfonic Acids; Transgenes | 2021 |